These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8378244)
1. In vivo validation of the release rate and palatability of remoxipride-modified release suspension. Sjöqvist R; Graffner C; Ekman I; Sinclair W; Woods JP Pharm Res; 1993 Jul; 10(7):1020-6. PubMed ID: 8378244 [TBL] [Abstract][Full Text] [Related]
2. Nanosponge-based pediatric-controlled release dry suspension of Gabapentin for reconstitution. Rao MR; Bhingole RC Drug Dev Ind Pharm; 2015; 41(12):2029-36. PubMed ID: 26006328 [TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. Undre N; Dickinson J BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389 [TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of remoxipride and the gastrointestinal transit of 111In-marked extended-release coated spheres. Graffner C; Wagner Z; Nilsson MI; Widerlöv E Pharm Res; 1990 Jan; 7(1):54-8. PubMed ID: 2137217 [TBL] [Abstract][Full Text] [Related]
6. Oral sustained-release suspension based on a novel taste-masked and mucoadhesive carrier-ion-exchange fiber. Yuan J; Liu T; Li H; Shi T; Xu J; Liu H; Wang Z; Wang Q; Xu L; Wang Y; Li S Int J Pharm; 2014 Sep; 472(1-2):74-81. PubMed ID: 24882038 [TBL] [Abstract][Full Text] [Related]
7. Influence of the dosing interval on prolactin release after remoxipride. Movin-Osswald G; Hammarlund-Udenaes M; Von Bahr C; Eneroth P; Walton-Bowen K Br J Clin Pharmacol; 1995 May; 39(5):503-10. PubMed ID: 7669486 [TBL] [Abstract][Full Text] [Related]
8. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Stevens J; Ploeger BA; van der Graaf PH; Danhof M; de Lange EC Drug Metab Dispos; 2011 Dec; 39(12):2275-82. PubMed ID: 21903866 [TBL] [Abstract][Full Text] [Related]
9. Bioavailability of potassium from three dosage forms: suspension, capsule, and solution. Melikian AP; Cheng LK; Wright GJ; Cohen A; Bruce RE J Clin Pharmacol; 1988 Nov; 28(11):1046-50. PubMed ID: 3243918 [TBL] [Abstract][Full Text] [Related]
10. Correlation between the bioavailability of microencapsulated bacampicillin hydrochloride in suspension and in vitro microcapsule dissolution. Sjövall J; Sjöqvist R; Huitfeldt B; Nyqvist H J Pharm Sci; 1984 Feb; 73(2):141-5. PubMed ID: 6707871 [TBL] [Abstract][Full Text] [Related]
11. Critical dissolution tests of oral systems based on statistically designed experiments. II. In vitro optimization of screened variables on ER-coated spheres for the establishment of an in vitro/in vivo correlation. Abuzarur-Aloul R; Gjellan K; Sjölund M; Graffner C Drug Dev Ind Pharm; 1998 Mar; 24(3):203-12. PubMed ID: 9876576 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients. Widerlöv E; Franzén G; Jansson P; Movin G Int Clin Psychopharmacol; 1990 Apr; 5(2):125-34. PubMed ID: 1974271 [TBL] [Abstract][Full Text] [Related]
13. Studies on the development of taste-masked suspension of chloroquine. Chandibhamar V; Yadav MR; Murthy RS Boll Chim Farm; 2004 Dec; 143(10):377-82. PubMed ID: 15881817 [TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of taste-masked donepezil hydrochloride orally disintegrating tablets. Yan YD; Woo JS; Kang JH; Yong CS; Choi HG Biol Pharm Bull; 2010; 33(8):1364-70. PubMed ID: 20686233 [TBL] [Abstract][Full Text] [Related]
15. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers. Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557 [TBL] [Abstract][Full Text] [Related]
16. Remoxipride: pharmacokinetics and effect on plasma prolactin. Movin-Osswald G; Hammarlund-Udenaes M Br J Clin Pharmacol; 1991 Sep; 32(3):355-60. PubMed ID: 1685665 [TBL] [Abstract][Full Text] [Related]
17. Preparation of microcapsules masking the bitter taste of enoxacin by using one continuous process technique of agglomeration and microencapsulation. Ueda M; Nakamura Y; Makita H; Kawashima Y J Microencapsul; 1993; 10(4):461-73. PubMed ID: 8263675 [TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics of controlled release and immediate release formulations of remoxipride in patients with chronic schizophrenia. Tench D; Soni SD; Ashwood T; Movin G Psychopharmacology (Berl); 1990; 101(1):132-6. PubMed ID: 1971445 [TBL] [Abstract][Full Text] [Related]
19. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. Stevens J; Ploeger BA; Hammarlund-Udenaes M; Osswald G; van der Graaf PH; Danhof M; de Lange EC J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):463-77. PubMed ID: 22791078 [TBL] [Abstract][Full Text] [Related]
20. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. Movin-Osswald G; Hammarlund-Udenaes M J Pharmacol Exp Ther; 1995 Aug; 274(2):921-7. PubMed ID: 7636755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]